S1609

Any Site

Indiana University (IU)

• Eskenazi Hospital
• IU Health North/ Schwarz Cancer Center
• IU Health West
• Indiana University Hospital / IU Simon Cancer Center
• Spring Mill Medical Center

• A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
  Adams S;Othus M;Patel SP;Miller KD;Chugh R;Schuetze SM;Chamberlin MD;Haley BJ;Storniolo AMV;Reddy MP;Anderson SA;Zimmerman CT;O'Dea AP;Mirshahidi HR;Ahnert JR;Brescia FJ;Hahn O;Raymond JM;Biggs DD;Connolly RM;Sharon E;Korde LA;Gray RJ;Mayerson E;Plets M;Blanke CD;Chae YK;Kurzrock R;
• The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas
  Dai C;Liang S;Sun B;Kang J;
• Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
  Wagner MJ;Othus M;Patel SP;Ryan C;Sangal A;Powers B;Budd GT;Victor AI;Hsueh CT;Chugh R;Nair S;Leu KM;Agulnik M;Sharon E;Mayerson E;Plets M;Blanke C;Streicher H;Chae YK;Kurzrock R;
• A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
  Patel SP;Othus M;Chae YK;Giles FJ;Hansel DE;Singh PP;Fontaine A;Shah MH;Kasi A;Baghdadi TA;Matrana M;Gatalica Z;Korn WM;Hayward J;McLeod C;Chen HX;Sharon E;Mayerson E;Ryan CW;Plets M;Blanke CD;Kurzrock R;
• A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort
  Patel SP;Mayerson E;Chae YK;Strosberg J;Wang J;Konda B;Hayward J;McLeod CM;Chen HX;Sharon E;Othus M;Ryan CW;Plets M;Blanke CD;Kurzrock R;
• Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial
  Othus M;Patel SP;Chae YK;Dietrich E;Streicher H;Sharon E;Kurzrock R;
• SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer
  Patel SP;Guadarrama E;Chae YK;Dennis MJ;Powers BC;Liao CY;Ferri WA;George TJ;Sharon E;Ryan CW;Othus M;Lopez G;Blanke CD;Kurzrock R;
• Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
  Patel SP;Othus M;Chae YK;Huynh T;Tan B;Kuzel T;McLeod C;Lopez G;Chen HX;Sharon E;Streicher H;Ryan CW;Blanke C;Kurzrock R;
• Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
  Chae YK;Othus M;Patel S;Powers B;Hsueh CT;Govindarajan R;Bucur S;Kim HS;Chung LI;McLeod C;Chen HX;Sharon E;Streicher H;Ryan CW;Blanke C;Kurzrock R;
• First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
  Othus M;Patel SP;Chae YK;Dietrich E;Streicher H;Sharon E;Kurzrock R;
• Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)
  Chae YK;Othus M;Patel SP;Gerber DE;Tanvetyanon T;Kim HS;Chung LI;McLeod CM;Lopez G;Chen HX;Sharon E;Streicher H;Ryan CW;Blanke CD;Kurzrock R;
• Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
  Patel SP;Cano-Linson E;Chae YK;Schokrpur S;Lao CD;Powers BC;Victor AI;Onitilo AA;Shin S;Takebe N;Threlkel S;McLeod CM;Chen HX;Sharon E;Othus M;Ryan CW;Blanke CD;Kurzrock R;